Jazz Pharmaceuticals has achieved a significant milestone by becoming the first pharmaceutical company to receive FDA approval for a treatment targeting diffuse midline glioma with H3 K27M mutations. This rare form of brain cancer predominantly affects young individuals, and the approval marks a crucial advancement in addressing this challenging condition. The approval was granted for Modeyso (dordaviprone), an oral DRD2 antagonist obtained through Jazz’s acquisition of Chimerix for $935 million earlier this year. The drug is indicated for patients aged one or older whose cancer has progressed post prior therapy.
Patients afflicted with this high-grade glioma subtype typically face a grim prognosis, with limited treatment alternatives beyond radiotherapy and palliative care. Disease relapse is almost certain, and until now, there has been a lack of systemic therapy available for this condition. In the United States alone, it is estimated that around 2,000 individuals are diagnosed annually with H3 K27M-mutated glioma. Jazz is currently conducting a Phase 3 trial named ACTION in newly diagnosed, non-recurrent patients, with results anticipated next year. Positive outcomes from this trial could lead to broader FDA approval for Modeyso, potentially including its use as a first-line therapy.
Although Jazz has announced plans to launch Modeyso in the near future, the pricing details for the drug remain undisclosed. Administered as a weekly capsule, Chimerix had previously hinted at the drug’s blockbuster potential, despite the limited patient pool, based on a proposed ‘ultra-orphan’ pricing approach. Furthermore, the FDA approval of Modeyso comes with a valuable pediatric disease priority review voucher (PRV), which could facilitate the acceleration of Jazz’s other programs or be sold to another entity. Typically, PRVs are known to command prices exceeding $100 million.
The approval of Modeyso was supported by data from open-label studies involving 50 patients, showcasing an overall response rate of 22% and a median response duration of 10.3 months. Notably, approximately 73% of patients experienced a delay of at least six months in disease progression. Renowned neuro-oncology specialist Patrick Wen from Dana-Farber Cancer Institute and Harvard Medical School lauded the drug’s approval as a significant breakthrough for the field and a meaningful progression for patients. Echoing this sentiment, Joshua Allen, Chief Scientific Officer at Chimerix, emphasized that Modeyso’s approval not only offers clinicians a targeted therapeutic option but also signifies a positive shift in the post-diagnosis expectations for patients and families.
In addition to advancing its presence in the oncology sphere through the Chimerix acquisition, Jazz stands to benefit from the approval through the acquisition of a rare pediatric disease priority review voucher. This strategic move aligns with Jazz’s commitment to addressing unmet medical needs and underscores its dedication to pioneering innovative therapies in critical disease areas.
Key Takeaways:
– Jazz Pharmaceuticals has obtained FDA approval for Modeyso, a treatment for diffuse midline glioma with H3 K27M mutations, making it the first drugmaker to secure such an approval.
– The approval signifies a significant milestone in addressing a rare form of brain cancer that predominantly affects young individuals, providing hope for patients with limited treatment options.
– Jazz’s acquisition of Chimerix for $935 million facilitated access to Modeyso, highlighting the company’s strategic expansion into the oncology space.
– The FDA approval of Modeyso includes a valuable pediatric disease priority review voucher, enhancing Jazz’s potential for accelerating its other programs or generating additional revenue.
Read more on pharmaphorum.com